MDT: Bull Flag detected on 29 Jul 2026

MDT is forming a bull flag pattern on elevated volume (1.88x average), offering quality setup conditions. The pattern sits 16.3% below its 52-week high, with key support at $78.97 and initial resistance at $85.99. Structure score of 13.6/15 and breakout score of 12.5/13 indicate a well-defined formation. Current price of $86.88 is positioned just above the flag's upper band, with volume ratio of 1.88x confirming institutional participation. RSI at 65.06 suggests room for upside without extreme overbought conditions.

Medtronic reported fourth-quarter and full-year fiscal 2026 earnings on June 3, delivering what the company called its highest annual revenue growth in a decade. For the quarter ending April 24, 2026, Medtronic generated revenue of $9.807 billion, slightly ahead of the $9.730 billion consensus estimate. The company is facing competitive pressures, especially with the recent launch of its AI solutions and ongoing developments in the robotic surgery space. The upcoming MiniMed diabetes business IPO and subsequent spin-off are strategic moves designed to unlock value and streamline Medtronic's focus on its core, higher-growth segments. Medtronic plans to acquire SPR Therapeutics for about $650M in cash to add FDA-cleared temporary peripheral nerve stimulation tech.

A successful breakout above $85.99 resistance would target the conservative measure of $89.75, representing a 3.3% move from current price. Volume confirmation is critical—the current 1.88x ratio provides a solid foundation, though breakout should sustain above-average volume to confirm buying conviction. Win probability score of 77.37% suggests favorable historical odds. Invalidation occurs at key support of $78.97; a close below this level would negate the bull flag setup and suggest reversal toward prior consolidation zones.

Margin pressures from tariffs and a shifting product mix remain a near-term headwind. Guidance for fiscal year '27 factors in headwinds from tariffs, fuel costs, and anticipated M&A dilution. Medtronic is set to report Q1 earnings on September 1, 2026, with analysts expecting a 9.5% increase in EPS to $1.38, creating earnings volatility near the current setup window. Goldman Sachs restarted coverage on Medtronic with a Neutral rating and $84 target, below current price and indicating analyst caution. Beta of 0.6 provides downside protection in broad selloffs, but the healthcare sector is experiencing rotation pressures. Volume at 14.5M shares is elevated but could face withdrawal if broader market sentiment shifts.

We scan more than 6,000 NYSE and NASDAQ stocks every trading day and compare each detected pattern against a database of 370,000+ historical detections. Every setup is scored across three dimensions: Structure, Volume, and Breakout Readiness. Win probability is a calibrated estimate of how similar historical setups performed over the following 10 trading days. This is a swing trading tool built for multi-day holds. It is not built or tested for day trading.